Supermicro Announces Participation in Upcoming Investor Events
SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc. (SMCI), a global leader in high-performance, high-efficiency server and storage technology and green computing, announces that Kevin S. Bauer, Senior Vice President, Chief Financial Officer, and Patrick Wang, Senior Vice President, Strategy and Corporate Development, will participate in meetings with institutional investors at the following upcoming virtual events:
Event: |
Non-Deal Roadshow, hosted by Susquehanna International Group |
||
Dates: |
November 23-24 and November 30, 2020 |
||
|
|
||
Event: |
Wells Fargo TMT Summit 2020 |
||
Date: |
December 1, 2020 |
||
|
|
||
Event: |
Credit Suisse 24th Annual Technology Conference |
||
Date: |
December 2, 2020 |
About Super Micro Computer, Inc.
Supermicro (SMCI), the leading innovator in high-performance, high-efficiency server and storage technology, is a premier provider of advanced server Building Block Solutions® for Enterprise Data Center, Cloud Computing, Artificial Intelligence, and Edge Computing Systems worldwide. Supermicro is committed to protecting the environment through its “We Keep IT Green®” initiative and provides customers with the most energy-efficient, environmentally-friendly solutions available on the market.
Supermicro, Building Block Solutions and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.
SMCI-F
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006036/en/
Investor Relations Contact:
James Kisner
Vice President, Investor Relations
(669) 284-1259
email: [email protected]
Source: Super Micro Computer, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CIO Launches SmartCoby Ultra Slim SS5K on Kickstarter, Building on Ultra Slim 3K's Breakout Crowdfunding Success
- Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
- Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Credit Suisse, Susquehanna International Group of Companies, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share